NCT05393076View on ClinicalTrials.gov

Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

December 6, 2022

Study Completion Date

December 6, 2022

Conditions

Pruritus

Interventions

DRUG

Linerixibat

Linerixibat dose and administration as per study intervention.

Trial Locations (2)

32809

GSK Investigational Site, Orlando

78215

GSK Investigational Site, San Antonio

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY